These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15933242)

  • 1. Antiretroviral therapy in resource-poor countries: illusions and realities.
    Desvarieux M; Landman R; Liautaud B; Girard PM
    Am J Public Health; 2005 Jul; 95(7):1117-22. PubMed ID: 15933242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?
    Beck EJ; Mandalia S; DongmoNguimfack B; Pinheiro E; 't Hoen E; Boulet P; Stover J; Gupta A; Juneja S; Habiyambere V; Ghys P; Nunez C
    Glob Health Action; 2019; 12(1):1586317. PubMed ID: 30983547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scaling up antiretroviral treatment in resource-poor settings.
    Ellman T; Ford N
    Lancet; 2006 Aug; 368(9534):445-6. PubMed ID: 16890818
    [No Abstract]   [Full Text] [Related]  

  • 4. Utilization and costs of HIV antiretroviral drugs in Europe during the last ten years: Impact of generic antiretroviral drugs on cost reduction.
    Rwagitinywa J; Sommet A; Palmaro A; Montastruc JL; Lapeyre-Mestre M
    Health Policy; 2018 Mar; 122(3):237-242. PubMed ID: 29398158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generic antiretroviral drugs and HIV care: An economic review.
    Yazdanpanah Y; Schwarzinger M
    Med Mal Infect; 2016 Mar; 46(2):67-71. PubMed ID: 26905394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generic and branded drugs for the treatment of people living with HIV/AIDS.
    Bartlett JA; Muro EP
    J Int Assoc Physicians AIDS Care (Chic); 2007 Mar; 6(1):15-23. PubMed ID: 17329500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare?
    Chien CV
    PLoS One; 2007 Mar; 2(3):e278. PubMed ID: 17372625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Call for action to secure universal access to ART in developing countries.
    Orsi F; Carrieri MP; Coriat B; Delaporte E; Moatti JP; Spire B; Taverne B; Barré-Sinoussi F
    Lancet; 2010 May; 375(9727):1693-4. PubMed ID: 20472168
    [No Abstract]   [Full Text] [Related]  

  • 9. Generic antiretroviral drugs--will they be the answer to HIV in the developing world?
    Kumarasamy N
    Lancet; 2004 Jul 3-9; 364(9428):3-4. PubMed ID: 15234833
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of generic antiretroviral therapy (ART) and free ART programs on time to initiation of ART at a tertiary HIV care center in Chennai, India.
    Solomon SS; Lucas GM; Kumarasamy N; Yepthomi T; Balakrishnan P; Ganesh AK; Anand S; Moore RD; Solomon S; Mehta SH
    AIDS Care; 2013 Aug; 25(8):931-6. PubMed ID: 23216257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De-simplifying single-tablet antiretroviral treatments: uptake, risks and cost savings.
    Krentz HB; Campbell S; Lahl M; Gill MJ
    HIV Med; 2019 Mar; 20(3):214-221. PubMed ID: 30632660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
    Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
    PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs.
    Holmes CB; Coggin W; Jamieson D; Mihm H; Granich R; Savio P; Hope M; Ryan C; Moloney-Kitts M; Goosby EP; Dybul M
    JAMA; 2010 Jul; 304(3):313-20. PubMed ID: 20639565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinton brokers deal to lower price of antiretrovirals.
    Abimbola S
    BMJ; 2007 May; 334(7602):1026. PubMed ID: 17510129
    [No Abstract]   [Full Text] [Related]  

  • 15. Patents versus patients? Antiretroviral therapy in India.
    Havlir DV; Hammer SM
    N Engl J Med; 2005 Aug; 353(8):749-51. PubMed ID: 16120852
    [No Abstract]   [Full Text] [Related]  

  • 16. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Brazilian experiment: HIV drugs for all.
    Flaer PJ; Younis MZ
    J Health Care Finance; 2009; 36(2):90-6. PubMed ID: 20499725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up.
    Calmy A; Klement E; Teck R; Berman D; Pécoul B; Ferradini L
    AIDS; 2004 Dec; 18(18):2353-60. PubMed ID: 15622311
    [No Abstract]   [Full Text] [Related]  

  • 19. Designing an equitable strategy for allocating antiretroviral treatments.
    Capron AM; Reis A
    PLoS Med; 2005 Mar; 2(3):e69. PubMed ID: 15737013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral treatment in low-resource settings: what has changed in the last 10 years and what needs to change in the coming years?
    Mehta M; Semitala F; Lynen L; Colebunders R
    Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1287-96. PubMed ID: 23241186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.